Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia

Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T-ALL/LBL), although it is often used in combination regimens. We sought to understand differences in efficacy and toxicity whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimony, Shai, Liu, Yiwen, Valtis, Yannis K., Paolino, Jonathan D., Place, Andrew E., Brunner, Andrew M., Weeks, Lachelle D., Silverman, Lewis B., Vrooman, Lynda M., Neuberg, Donna S., Stone, Richard M., DeAngelo, Daniel J., Luskin, Marlise R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111357/
https://www.ncbi.nlm.nih.gov/pubmed/36508268
http://dx.doi.org/10.1182/bloodadvances.2022008280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111357/
https://www.ncbi.nlm.nih.gov/pubmed/36508268
http://dx.doi.org/10.1182/bloodadvances.2022008280

Ejemplares similares